Analysis of ~150 castration-resistant prostate cancer metastases revealed that SLC35F2 expression correlated with AR activity score, but that a subset of patient tumors had high expression of the transporter regardless of AR status [4]. This evidence concerns the gene SLC35F2 and prostate cancer.